Compare KMT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | WGS |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Industrial Machinery/Components | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 1994 | N/A |
| Metric | KMT | WGS |
|---|---|---|
| Price | $35.51 | $69.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $36.00 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 1.5M | 714.0K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,966,845,000.00 | N/A |
| Revenue This Year | $14.45 | $29.98 |
| Revenue Next Year | $7.95 | $24.85 |
| P/E Ratio | ★ $48.92 | $1,251.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.30 | $55.17 |
| 52 Week High | $42.03 | $170.87 |
| Indicator | KMT | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 34.60 |
| Support Level | $33.93 | $68.55 |
| Resistance Level | $41.89 | $76.21 |
| Average True Range (ATR) | 1.84 | 5.28 |
| MACD | -0.63 | -0.43 |
| Stochastic Oscillator | 8.25 | 6.76 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.